Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
Stefanie S. Schalm(Agios Pharmaceuticals (United States)), Klaus P. Hoeflich(Pivot)
Cited by 5
Related Papers
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
|Breast Cancer Research|2015|74
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition
|Proceedings of the National Academy of Sciences|2013|56
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
|Cancer Discovery|2024|43
Regulation of ERK3/MAPK6 expression by BRAF
|International Journal of Oncology|2006|32